HETERO LABS LTD III
GenericsHETERO LABS LTD III is a generic drug manufacturer focused on Infectious Disease, Cardiovascular, Neurology. Key products include LAMIVUDINE AND ZIDOVUDINE.
HETERO LABS LTD III's Key Drugs
HETERO LABS LTD III's core commercial portfolio centers on SACUBITRIL AND VALSARTAN, LEVOCETIRIZINE HYDROCHLORIDE, LOPINAVIR AND RITONAVIR, spanning Infectious Disease and Cardiovascular — its most strategically important drugs approved in the last 15 years.
Heart Failure
Hay Fever
HIV Infection
Pseudobulbar Affect
HETERO LABS LTD III's Recent FDA Approvals
HETERO LABS LTD III secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
HETERO LABS LTD III's Therapeutic Areas
HETERO LABS LTD III's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Cardiovascular, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
HETERO LABS LTD III's Top Competitors
HETERO LABS LTD III's closest competitors by therapeutic-area and drug-target overlap include Bristol-Myers Squibb, Pfizer, and WARNER CHILCOTT. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
HETERO LABS LTD III Pipeline Snapshot
Active clinical trials for HETERO LABS LTD III across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • SACUBITRIL AND VALSARTAN leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (4)
Discontinued (1)
Company Info
- First Approval
- 2008-04-25
- Latest
- 2026-06-08
- Applications
- 80